- Home
- ESRT vs SVRA Comparison
ESRT vs SVRA Comparison
Compare ESRT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESRT | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ESRT | SVRA |
|---|---|---|
| Price | $5.20 | $5.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $6.77 | ★ $7.33 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $768,270,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.52 | $430.87 |
| P/E Ratio | $20.66 | ★ N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.87 | $1.89 |
| 52 Week High | $8.76 | $7.01 |
Technical Indicators
Market Signals| Indicator | ESRT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 54.24 |
| Support Level | $4.87 | $5.47 |
| Resistance Level | $6.70 | $6.10 |
| Average True Range (ATR) | 0.16 | 0.28 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 74.42 | 65.75 |
Price Performance
Historical ComparisonAbout ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).